AzTrials
AzTrials

COVID-19 TestingNCT04775784

Determination of COVID-19 Related Virus in Central Nervous System

An observational study of COVID-19 Testing and CNS Disease, run by IRCCS San Raffaele at 1 site in Italy.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Coronavirus disease 2019 (COVID-19) is a highly infectious pandemic disease caused by SARS-CoV-2 virus. Central Nervous System (CNS) complications associated with COVID-19 might be secondary sequelae due to exuberant systemic innate-mediated hyper-inflammation, which may impair neurovascular endothelial function… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
COVID-19 Testing, CNS Disease, CNS Infection
What is being tested?
Determination of SARS-CoV2 presence in CNS
How many people
300 participants
Where
1 siteItaly
Study dates
17 Dec 2020to 31 Dec 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adult patients eligible to CNS surgery

Who may be able to join

  • Adult patients
  • Patients candidate for CNS surgery
  • Patients who have been tested for nasopharyngeal swab for SARS-CoV-2
  • Patients who have been tested for serology test for anti SARS-CoV-2 immunoglobulinG (IgG) and immunoglobulinM (IgM) antibodies
  • Patients able to sign informed consent

Who cannot join

  • Patients not meeting inclusion criteria

Trial locations and contacts

1 site in 1 country.

Italy1 site, 1 recruiting
  • IRCCS San Raffaele Scientific Institute

    Milan, 20132

    Laura Sincinelli, 003926435568, sincinelli.laura@hsr.it

    Recruiting

Other trials in Italy

About this study

Official title: Determination of SARS-Cov-2 Virus in Central Nervous System

Coronavirus disease 2019 (COVID-19) is a highly infectious pandemic disease caused by SARS-CoV-2 virus. Central Nervous System (CNS) complications associated with COVID-19 might be secondary sequelae due to exuberant systemic innate-mediated hyper-inflammation, which may impair neurovascular endothelial function, disrupt blood brain barrier (BBB), activates CNS innate immune signaling pathways, and induces parainfectious autoimmunity, potentially contributing to the CNS manifestations. Although the predominant clinical manifestation of SARS-CoV-2 is characterized by dyspnea, unremitting fever and hypoxemic respiratory failure, neurologic manifestations do occur in most hospitalized SARS-CoV-2 patients and include non-specific encephalopathy, psychosis, meningitis/encephalitis, myelitis, cerebrovascular events, Guillain-Barre' syndrome, and cranial or peripheral neuropathies, such as anosmia and ageusia. To date, data about primary CNS involvement due to neurotropism and direct neuroinvasion are still lacking.

Read the detailed description

Determination of SARS-CoV-2 presence in central nervous system

Being tested
Determination of SARS-CoV2 presence in CNS
Keywords
SARS-Cov-2, CNS infection, Coronavirus, Brain
Medical subject headings
Central Nervous System Diseases, Central Nervous System Infections, Coronavirus Infections

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Determination of SARS-CoV2 presence in CNSDiagnostic test

    Brain tissue sampling

Study groups in NCT04775784
Study groupRoleWhat they receive
Adult neurosurgical patientsAdult, both sex, neurosurgical patients candidate for intracranial surgery, able to sign informed consent.
Receives: Diagnostic Test: Determination of SARS-CoV2 presence in CNS

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Determination of SARS-CoV-2 presence in the CNS

    Brain tissue sampling analysis

    Measured: Surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Mar 2021
  2. Study start17 Dec 2020
  3. Primary completion1 Jun 2022
  4. Study completion31 Dec 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
300 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04775784
Sponsor's protocol ID
NCH08-2020
Status last verified
Apr 2023
First submitted
25 Feb 2021
Last updated
18 Apr 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Noorwali AA, Turkistani AM, Asiri SI, Trabulsi FA, Alwafi OM, Alzahrani SH, Rashid MM, Hegazy SA, Alzaydi MD, Bawakid KO. Descriptive epidemiology and characteristics of confirmed cases of Middle East respiratory syndrome coronavirus infection in the Makkah Region of Saudi Arabia, March to June 2014. Ann Saudi Med. 2015 May-Jun;35(3):203-9. doi: 10.5144/0256-4947.2015.203.

    PubMed 26409794
  • Montalvan V, Lee J, Bueso T, De Toledo J, Rivas K. Neurological manifestations of COVID-19 and other coronavirus infections: A systematic review. Clin Neurol Neurosurg. 2020 Jul;194:105921. doi: 10.1016/j.clineuro.2020.105921. Epub 2020 May 15.

    PubMed 32422545
  • Liotta EM, Batra A, Clark JR, Shlobin NA, Hoffman SC, Orban ZS, Koralnik IJ. Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients. Ann Clin Transl Neurol. 2020 Nov;7(11):2221-2230. doi: 10.1002/acn3.51210. Epub 2020 Oct 5.

    PubMed 33016619
  • Berger JR. COVID-19 and the nervous system. J Neurovirol. 2020 Apr;26(2):143-148. doi: 10.1007/s13365-020-00840-5. Epub 2020 May 23.

    PubMed 32447630
  • Najjar S, Najjar A, Chong DJ, Pramanik BK, Kirsch C, Kuzniecky RI, Pacia SV, Azhar S. Central nervous system complications associated with SARS-CoV-2 infection: integrative concepts of pathophysiology and case reports. J Neuroinflammation. 2020 Aug 6;17(1):231. doi: 10.1186/s12974-020-01896-0.

    PubMed 32758257
  • Liu J, Xie W, Wang Y, Xiong Y, Chen S, Han J, Wu Q. A comparative overview of COVID-19, MERS and SARS: Review article. Int J Surg. 2020 Sep;81:1-8. doi: 10.1016/j.ijsu.2020.07.032. Epub 2020 Jul 26.

    PubMed 32730205
  • Kumar A, Pareek V, Prasoon P, Faiq MA, Kumar P, Kumari C, Narayan RK. Possible routes of SARS-CoV-2 invasion in brain: In context of neurological symptoms in COVID-19 patients. J Neurosci Res. 2020 Dec;98(12):2376-2383. doi: 10.1002/jnr.24717. Epub 2020 Aug 31.

    PubMed 32869376
  • Song E, Zhang C, Israelow B, Lu-Culligan A, Prado AV, Skriabine S, Lu P, Weizman OE, Liu F, Dai Y, Szigeti-Buck K, Yasumoto Y, Wang G, Castaldi C, Heltke J, Ng E, Wheeler J, Alfajaro MM, Levavasseur E, Fontes B, Ravindra NG, Van Dijk D, Mane S, Gunel M, Ring A, Kazmi SAJ, Zhang K, Wilen CB, Horvath TL, Plu I, Haik S, Thomas JL, Louvi A, Farhadian SF, Huttner A, Seilhean D, Renier N, Bilguvar K, Iwasaki A. Neuroinvasion of SARS-CoV-2 in human and mouse brain. bioRxiv [Preprint]. 2020 Sep 8:2020.06.25.169946. doi: 10.1101/2020.06.25.169946.

    PubMed 32935108
  • Virhammar J, Kumlien E, Fallmar D, Frithiof R, Jackmann S, Skold MK, Kadir M, Frick J, Lindeberg J, Olivero-Reinius H, Ryttlefors M, Cunningham JL, Wikstrom J, Grabowska A, Bondeson K, Bergquist J, Zetterberg H, Rostami E. Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid. Neurology. 2020 Sep 8;95(10):445-449. doi: 10.1212/WNL.0000000000010250. Epub 2020 Jun 25.

    PubMed 32586897
  • Espindola OM, Brandao CO, Gomes YCP, Siqueira M, Soares CN, Lima MASD, Leite ACCB, Torezani G, Araujo AQC, Silva MTT. Cerebrospinal fluid findings in neurological diseases associated with COVID-19 and insights into mechanisms of disease development. Int J Infect Dis. 2021 Jan;102:155-162. doi: 10.1016/j.ijid.2020.10.044. Epub 2020 Oct 28.

    PubMed 33127503
  • Bernard-Valnet R, Pizzarotti B, Anichini A, Demars Y, Russo E, Schmidhauser M, Cerutti-Sola J, Rossetti AO, Du Pasquier R. Two patients with acute meningoencephalitis concomitant with SARS-CoV-2 infection. Eur J Neurol. 2020 Sep;27(9):e43-e44. doi: 10.1111/ene.14298. Epub 2020 May 30. No abstract available.

    PubMed 32383343
  • Paniz-Mondolfi A, Bryce C, Grimes Z, Gordon RE, Reidy J, Lednicky J, Sordillo EM, Fowkes M. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J Med Virol. 2020 Jul;92(7):699-702. doi: 10.1002/jmv.25915.

    PubMed 32314810
  • Solomon IH, Normandin E, Bhattacharyya S, Mukerji SS, Keller K, Ali AS, Adams G, Hornick JL, Padera RF Jr, Sabeti P. Neuropathological Features of Covid-19. N Engl J Med. 2020 Sep 3;383(10):989-992. doi: 10.1056/NEJMc2019373. Epub 2020 Jun 12. No abstract available.

    PubMed 32530583
  • Pereira A. Long-Term Neurological Threats of COVID-19: A Call to Update the Thinking About the Outcomes of the Coronavirus Pandemic. Front Neurol. 2020 Apr 17;11:308. doi: 10.3389/fneur.2020.00308. eCollection 2020. No abstract available.

    PubMed 32362868
  • Yachou Y, El Idrissi A, Belapasov V, Ait Benali S. Neuroinvasion, neurotropic, and neuroinflammatory events of SARS-CoV-2: understanding the neurological manifestations in COVID-19 patients. Neurol Sci. 2020 Oct;41(10):2657-2669. doi: 10.1007/s10072-020-04575-3. Epub 2020 Jul 28.

    PubMed 32725449

Questions about this trial

What is this clinical trial studying?

An observational study of COVID-19 Testing and CNS Disease, run by IRCCS San Raffaele at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 18 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Laura Sincinelli (00390226435568, sincinelli.laura@hsr.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Determination of SARS-CoV-2 presence in the CNS (time frame: Surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04775784, which also lists 15 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Apr 2023; AzTrials last refreshed its copy on 7 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in